Clinical Comparison of Alb-PRF Vs PRF on Postoperative Morbidity Following FGG Harvesting
NCT ID: NCT06567548
Last Updated: 2024-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
39 participants
INTERVENTIONAL
2025-01-31
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study settings:
* The study will be conducted in the Oral Medicine and Periodontology department, Faculty of Dentistry - Cairo University, Egypt.
* Patients will be selected from the Department of Oral Medicine and Periodontology-Cairo University outpatient clinic.
Expected Duration of Participation and Number of Participants: Research Duration: 28 days Number of Participants: 39 volunteers
Work Plan:
During the first visit, preoperative photographs will be taken. Then, participants will be randomly assigned (using a website) into three groups:
Group A: Application of Alb-PRF at the donor site of the free gingival graft. Group B: Application of PRF at the donor site of the free gingival graft. Control: Application of Gelatin Sponge at the donor site.
* 10 ml of venous blood will be drawn from the patient to prepare Alb-PRF and PRF membranes for placement at the donor site.
* The membrane or gelatin sponge will be placed at the donor site and sutured.
Postoperative Protocol:
After surgery, patients will be instructed to take 600 mg of ibuprofen, and 0.12% chlorhexidine gluconate mouthwash for two weeks postoperatively.
Analgesics will be recommended only if there is pain, and no antibiotics will be prescribed.
Patients will receive verbal and written dietary advice postoperatively. They will be encouraged to avoid heat sources and adhere to a diet of cold and soft foods.
Cleaning the adjacent palatal side of the surgical site will be prohibited to avoid irritation, while gentle cleaning will be recommended after dressing removal.
In case of postoperative problems such as unusual bleeding or gum recession, patients will be provided with contact information for their physician for early intervention.
During Visual Analog Scale (VAS) pain recording, patients will be instructed only to describe pain from the palate and to track additional analgesic intake and consumed tablets. Follow-up visits will be scheduled on days 3, 7, 14, 21, and 28 postoperatively.
Postoperative Follow-up:
Palatal sutures will be removed after 7 days post-surgery. On days 14, 21, and 28, wound healing, tissue color match, complete re-epithelialization of the wound, and clinical wound healing area will be monitored.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Intra-Oral Examination: Confirm the patient's eligibility based on predefined criteria.
* Phase I Therapy: Perform thorough supragingival scaling and subgingival debridement.
* Plaque Control: Ensure the patient maintains proper mechanical and chemical plaque control.
Clinical Procedure: Free Gingival Graft (FGG) Harvesting
* Preparation: All procedures will be done under sterile conditions and local anesthesia
* FGG Harvesting:
* FGG will be harvested from the palate).
* Make two horizontal incisions (coronal incision 2mm above the gingival margin) and two vertical incisions to outline the graft area.
* Insert a blade along the coronal incision, perpendicular to the bone, then move parallel to the hard palate in a mesiodistal direction to detach the graft while maintaining uniform thickness and avoiding the palatal periosteum.
* Place the graft on sterile saline gauze to prevent shrinkage.
* Control Group:
* Apply an absorbable gelatin sponge to the wound after FGG harvesting.
* Secure with compressive palatal sling sutures ( 5-0 polypropylene).
* PRF Group:
* PRF Preparation: Collect 10 ml of intravenous blood, and centrifuge at 3000 Rounds Per Minute (RPM) for 10 minutes. Extract the PRF clot and form a membrane.
* Apply the PRF membrane over the donor site and secure it with criss-cross sutures ( 5-0 polypropylene).
* Alb-PRF Group:
* Alb-PRF Preparation: Collect 10 ml of intravenous blood, and centrifuge at 700 RPM for 8 minutes. Heat the upper layer to 75°C for 10 minutes to form albumin gel, then cool.
Mix the albumin gel with liquid PRF to form Alb-PRF.
* Apply the Alb-PRF membrane over the donor site and secure it with criss-cross sutures ( 5-0 polypropylene).
Postsurgical Care
* Pain Management: Take Ibuprofen 600 mg as needed.
* Mouthwash: Use 0.12% chlorhexidine gluconate for two weeks.
* Dietary Instructions: Follow a cold, soft diet; avoid hot foods.
* Oral Hygiene: Avoid brushing near the surgical site; gentle brushing is allowed after pack removal.
* Emergency Contact: Provided for issues like abnormal bleeding.
* Pain Assessment: Use the Visual Analog Scale (VAS) to assess pain in the palate.
* Follow-Up: Scheduled for 3, 7, 14, 21, and 28 days post-surgery.
* Suture Removal: 7 days after surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
absorbable gelatin sponge
control group
An absorbable gelatin sponge is a sterile hemostatic agent primarily composed of purified porcine-derived gelatin. It is widely utilized in surgical procedures to control bleeding
Platelet-rich fibrin (PRF) group
Platelet-rich fibrin (PRF) is a biomaterial derived from the patient's own blood, utilized primarily in regenerative medicine and surgery due to its rich content of growth factors and its ability to promote healing.
Platelet-rich fibrin (PRF)
Platelet-rich fibrin (PRF) is a biomaterial derived from the patient's own blood, utilized primarily in regenerative medicine and surgery due to its rich content of growth factors and its ability to promote healing.
Albumin Platelet Rich- Fibrin (Alb-PRF) group:
Albumin Platelet-Rich Fibrin (Alb-PRF) is an innovative biomaterial that combines the regenerative properties of platelet-rich fibrin (PRF) with the structural and functional benefits of albumin. This mixture is designed to enhance tissue healing and regeneration by utilizing autologous blood components.
Albumin Platelet Rich- Fibrin
is an innovative biomaterial that combines the regenerative properties of platelet-rich fibrin (PRF) with the structural and functional benefits of albumin. This mixture is designed to enhance tissue healing and regeneration by utilizing autologous blood components.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
control group
An absorbable gelatin sponge is a sterile hemostatic agent primarily composed of purified porcine-derived gelatin. It is widely utilized in surgical procedures to control bleeding
Platelet-rich fibrin (PRF)
Platelet-rich fibrin (PRF) is a biomaterial derived from the patient's own blood, utilized primarily in regenerative medicine and surgery due to its rich content of growth factors and its ability to promote healing.
Albumin Platelet Rich- Fibrin
is an innovative biomaterial that combines the regenerative properties of platelet-rich fibrin (PRF) with the structural and functional benefits of albumin. This mixture is designed to enhance tissue healing and regeneration by utilizing autologous blood components.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Medically free patients
3. Adult patients above 18 years old.
4. Patients accepting a 1-month follow-up period (cooperative patients).
5. Patients who will provide an informed consent.
Exclusion Criteria
2. Pregnant and lactating women
3. Patients with poor oral hygiene
4. Patients who had previous periodontal surgery in the area of interest
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samar Idris Hamelin Idris
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Enji Mahmoud, Phd
Role: STUDY_DIRECTOR
Cairo University
Sarah Elbanna, Phd
Role: STUDY_DIRECTOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cairo University
Cairo, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Samar Idris Hamadelnil Idris Samar Idris, master
Role: CONTACT
Phone: 01273600331
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17624
Identifier Type: -
Identifier Source: org_study_id